Lay Description

Purpose/Objectives: With REMD’s glucagon receptor antagonist, we propose to provide a comprehensive examination of the effect of elevated plasma glucagon concentrations in T2D patients on:  (i) glucose tolerance; (ii) insulin sensitivity in liver, muscle, and adipocytes; (iii) beta cell function; (iv) adipocyte inflammation.

Clinical Relevance: Glucagon is a hormone normally produced by pancreas which is usually elevated in patients with diabetes and we want to see if we block the effect of glucagon with the drug called REMD-477 we can improve glucose levels.


  • Diabetes
IRB Number
NCT Number registration not required
Open to Enrollment


Eligible Ages
Eligible Genders
Accepts Healthy Volunteers

Inclusion Criteria

Good general health determined by medical  history, physical exam, and routine blood chemistries; BMI = 25-40 kg/m2; HbA1c 7.5-10.0%; Type 2 Diabetics who are drug naïve or treated with metformin, sulfonylureas, SGLT-2 inhibitors or any combination thereof.

Exclusion Criteria

Type 1 diabetes, Subjects treated with GLP-1 RAs or insulin

Study Design

Arm Groups

Study Contact

Ralph DeFronzo
(210) 567-6691

Andrea Hansis-diarte
+1 (210) 617-5300

Andrea Hansis-diarte
+1 (210) 617-5300

Ralph DeFronzo
(210) 567-6691

Principal Investigator
Ralph DeFronzo